RNA Outsourcing Videos

1. The Latest And Greatest Technological Innovations In mRNA-LNP Production 2/10/2025

   In this segment, Replicate Biosciences’ Andy Geall, Qian Ruan, & Alex Aust identify the most promising technological and raw material innovations that are influencing the drug substance and drug product production processes at CDMOs.

2. Mastering The Complexities Of Gene Therapy Document Writing 5/20/2025

   Gain the insight and strategic flexibility needed to confidently navigate the unique scientific, regulatory, and documentation challenges of gene therapy development.

3. How Outsourcing mRNA Development Has Evolved Since COVID 2/10/2025

   Advancing RNA panelists Alex Aust, Qian Ruan, and Andy Geal share their thoughts on the ways in which outsourcing firms are approaching mRNA development today, as well as why outsourcing — as opposed to building a GMP facility — remains critical for (x)RNA biotechs today.

4. Who's In Charge? How To Ensure Effective Trial Oversight, Leadership 3/19/2025

   Gain valuable insights into the role of sponsor-side Clinical Operations leadership, the risks of over-relying on CROs, and key strategies for fostering collaboration between sponsors and partners.

5. How A Sponsored CMC Platform Accelerates mRNA Projects Into The Clinic 1/31/2023

   Developing a client-sponsored Target Product Profile (TPP) and Analytical Target Profile (ATP) is critical to move your drug product to clinic efficiently and meet acceptance criteria.

6. Our Experience Creates Reliable Results 6/27/2024

   Hear from inSeption Group clients as they share their experiences, recount their journeys and highlight the exceptional service and support they received.

7. Face- Phase-Off: Matching CDMO Capabilities To Your mRNA-LNP Development Stage 2/10/2025

   There are many different criteria for selecting a CDMO for your mRNA products. Arcturus’ Qian Ruan explains that a product’s stage of development and the specific needs inherent to that phase of development should be an important guide for companies today, especially given the expansion of the outsourcing sector and the wide range of capabilities.

8. Scale-Up And Production Of Key Lipids Used In mRNA Delivery Systems 2/13/2025

   Discover key strategies for overcoming challenges in the industrial-scale production of ionizable and PEG lipids to optimize mRNA vaccine formulation and address critical manufacturing requirements.

9. mRNA's Impact On Cost And Capacity To Surge Biopharma Production 5/22/2023

   TFF Pharmaceuticals’ Kayla Hannon and University of Sheffield’s Dr. Zoltán Kis discuss the cost and capacity implications of therapeutic demand surges in this Surge Manufacturing for Biopharma Resilience segment.

10. How To Bring Your LNP Formulation To Clinical/Commercial Manufacturing 5/23/2024

    Gain valuable insights into key considerations when selecting lipid excipients for LNP formulations and the process development steps necessary to advance them to GMP manufacturing and clinical trials.